Delivery Order SPE2DB24D3014-SPE2DB24FKSDX

Award Date 9/10/24
Potential Completion Date 9/11/24
Potential Value $2.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of $1,200.93 worth of Tresiba FlexTouch 200 unit/mL 3mL insulin products. The order has an ultimate completion date of April 8, 2024. This award is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance...
This is a $23,508.27 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the supply of 4,565,362,864 units of Tresiba FlexTouch 100 unit/mL 3mL, a prescription insulin product, with a performance period through August 7, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through...
The U.S. Defense Logistics Agency (DLA) awarded a $1,334.04 firm fixed price delivery order contract to AmerisourceBergen Drug Corp to supply Tresiba FlexTouch 100 Unit/mL 3mL insulin products. This delivery order is under a larger indefinite delivery contract with DLA Troop Support Medical, valued up to $999,999,999, which enables the government to efficiently procure a wide range of pharmaceutical and medical supplies to support military healthcare programs. The award does not have a set-aside...
The Defense Logistics Agency (DLA) has awarded a delivery order contract to Amerisourcebergen Drug Corp Corporate Office Division, a major pharmaceutical distributor, for the supply of TRESIBA FLEXTOUCH 200 UNIT/ML 3ML insulin medication. The $18,948.75 firm-fixed-price contract has an ultimate completion date of October 10, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide TRESIBA FLEXTOUCH 100 UNIT/ML 3ML pharmaceutical products. The contract has a ceiling value of $2,289.66 and a period of performance through April 12, 2024. This delivery order is part of Amerisourcebergen Drug Corp's indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00 through December 31,...
This is a $2,344.66 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the supply of TRESIBA FLEXTOUCH 100 UNIT/ML 3ML pharmaceutical products, with a period of performance through July 1, 2024. Amerisourcebergen, a major pharmaceutical distributor, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a comprehensive range of pharmaceutical...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation, to provide 4,563,803,876 units of TRESIBA FLEXTOUCH 200 UNIT/ML 3ML. The delivery order is valued at $6,882.90 and has a completion date of February 29, 2024. This award is under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp that has a potential value of up to $999,999,999.00 and a...
This is a $1,601.24 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the supply of 4,565,925,708 units of Tresiba FlexTouch 200 Unit/ML 3ML insulin medication. This delivery order falls under a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for the provision of a wide range of pharmaceutical and medical supplies...
This federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical is a delivery order placed with AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for TRESIBA FLEXTOUCH 100 UNIT/ML 3ML. The contract has a firm fixed price of $2,782.23 and a completion date of January 9, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order valued at $4,402.92 to Amerisourcebergen Drug Corp, a for-profit pharmaceutical distributor, for the supply of TRESIBA FLEXTOUCH 200 UNIT/ML 3ML medication. This order was placed under an existing indefinite delivery contract (IDC) held by Amerisourcebergen with DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary vehicle for Amerisourcebergen...
  • SPE2DB24D3014
    Indefinite Delivery Contract
  • SPE2DB24D3014-SPE2DB24FKSDX
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $2,401.86 to Amerisourcebergen Drug Corp, Corporate Office Division, for the supply of Tresiba FlexTouch 200 Unit/mL 3mL pharmaceutical products. This delivery order is associated with a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for the provision of a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation and the ultimate completion date is September 11, 2024.

Generated 12/10/24, 2:11 PM